Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean acetyl acid and approved type?
Displaying drugs 301 - 325 of 10963 in total

Potassium

Potassium is an essential nutrient, like Calcium and Magnesium. It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. Many conditions and diseases interfere with normal body potassium balance, and underconsumption of potassium is one example. Hypokalemia (low potassium) or hyperkalemia (high potassium)...
Approved
Experimental
Matched Description: … Potassium is an essential nutrient, like [Calcium] and [Magnesium]. ... They are available in an assortment of tablet, injection, and other forms, depending on the setting and …
Matched Mixtures name: … New Chapter's D'adamo 4 Your Type Multiple for Type O …

Tirzepatide

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials....
Approved
Investigational
Matched Description: … [A246260] Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty ... for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor ... [L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386] …

Phylloquinone

Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin.[L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X.[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II,...
Approved
Investigational
Matched Description: … [L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the …

Anethole

Approved
Experimental

Infigratinib

Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a...
Approved
Investigational
Matched Description: … FDA-approved test. ... [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR ... [L34304] This approval follows [pemigatinib], another FGFR inhibitor approved by the FDA for the same …
Matched Categories: … Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors …

Osimertinib

Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ... (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved ... Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific …

Sulfamethazine

A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.
Approved
Investigational
Vet approved

Latanoprostene bunod

Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure. As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle...
Approved
Investigational
Matched Description: … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution ... Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester ... In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone. …

Asparaginase Erwinia chrysanthemi

Asparaginase Erwinia chrysanthemi is an asparaginase-specific enzyme derived from Erwinia chrysanthemi used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in...
Approved
Investigational
Matched Description: … It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA ... _ used as an anticancer agent. ... [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the …

Olopatadine

Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of doxepin, which has a minimal anti-allergic activity. Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and...
Approved
Matched Iupac: … acid ... -(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaen-5-yl]acetic …
Matched Description: … An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of …

Laropiprant

Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.
Approved
Investigational
Withdrawn
Matched Iupac: … acid ... 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic …
Matched Description: … Laropiprant is an ingredient in the EMA-withdrawn product Pelzont. …

Migalastat

Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Description: … ., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than ... an oral pharmacological chaperone of alpha-Gal A for the treatment of Fabry disease in adults who have ... [L4274] Migalastat (approved and sold under Amicus Therapeutics' brand name Galafold) is subsequently …

Manidipine

Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Approved
Investigational
Matched Description: … Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive …

Phenformin

A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Approved
Investigational
Withdrawn
Matched Description: … Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis …

Sotagliflozin

Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Description: … 26, 2019, for the treatment of type 1 diabetes. ... Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved ... for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 …

Snail, unspecified

Snail, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Matched Description: … It is not an approved drug. ... Snail, unspecified is an animal extract used in some OTC (over-the-counter) products. …

Cinnamyl alcohol

Cinnamyl alcohol is a naturally occurring compound that is found within cinnamon. Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as DB14184 within commercial products. Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% . Sensitivity...
Approved
Experimental

Dasatinib

Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein...
Approved
Investigational
Matched Description: … [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] ... Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome …

Fosdenopterin

Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … in patients with MoCD type A,[L32163] becoming the first and only therapy approved for the treatment ... Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting ... [L43075] In September 2022, the EMA approved the use of fosdenopterin.[L43372,L43433] …

Methocarbamol

Methocarbamol was developed in the early 1950s as a treatment for muscle spasticity and the associated pain.[A178441,A178450] It is a guaiacol glyceryl ether. Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of...
Approved
Vet approved
Matched Description: … [L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265] ... [L6295] A combination product with [acetylsalicylic acid] and [codeine] is available in Canada by prescription ... [Label,L6268] In Canada, methocarbamol can be sold as an over the counter oral medicine at a lower dose …
Matched Mixtures name: … Muscle & Back Pain Asa 325 Mg Methocarbamol 400 Mg & Acetylsalicylic Acid 325 mg ... Extra Strength Muscle & Back Pain Asa 500 Mg Methocarbamol 400 Mg & Acetylsalicylic Acid 500 mg …
Matched Categories: … Carbamic Acid Esters …

Nifedipine

Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine.[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer...
Approved
Matched Description: … Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar …

Ansuvimab

Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%.[A225933, A225938] Virtually all steps of the EBOV lifecycle have been targeted for therapeutic development. However, to date, the most successful...
Approved
Investigational
Matched Description: … Ansuvimab is just the second FDA-approved treatment for EVD.[L29560] ... antibodies (mAbs) against the GP1,2 surface glycoprotein, as evidenced by the previously approved ... INMAZEB™ (REGN-EB3, a cocktail of [atoltivimab], [odesivimab], and [maftivimab]), the now approved ansuvimab …

Viltolarsen

Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of ... A218176] Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an …

Maralixibat

Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat.[A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, rifampin, ursodeoxycholic acid, cholestyramine, naltrexone, and...
Approved
Investigational
Matched Description: … Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor ... [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541] ... [A239249] Maralixibat represents the first FDA-approved treatment for cholestatic pruritus in patients …
Matched Categories: … Ileal bile acid transport inhibitor ... Ileal Bile Acid Transporter Inhibitor …

Gliquidone

Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Approved
Investigational
Matched Description: … It is an ATP-dependent K+ (KATP) channel blocker. ... Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. …
Displaying drugs 301 - 325 of 10963 in total